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When I became Editor in Chief of Wiley’s WIREsNanomedicine and Nanobiotechnology, I felt
one of the most important issues was that the
publication is dedicated to nanomedicines. This
essentially suggested that nanotechnology would be
transitioning into the actual development of human
therapeutics. Recently, this movement has begun. We
have seen the initiation of multiple clinical trials of
nanomaterials both for therapeutics and for medical
devices. While this is exciting and encouraging, it
is important to realize that nanotechnology now
has to come to grips with the regulatory issues
associated with a therapeutic approval process. This
process is complex and expensive, but is necessary
regardless of the nanomaterial or application. Many
individuals who specialize in material science,
analytical chemistry, or physics have not had prior
experience with the regulatory process for either
human therapeutics or medical devices. As such, I
think it is worthwhile to review briefly the approval
process for a human therapeutic.
First, while the procedures required to approve
a drug were varied around the world, there has been
recent convergence to these processes facilitated by
the International Conference on Harmonization. Fun-
damental to the development process is the ability
to characterize critical product attributes that ensure
the identity, strength, quality, purity, and potency
of the final product. New technologies will require
new approaches to accomplish this assessment. In
addition, at least four different sets of studies are
necessary before a product can be submitted for
approval for use in humans. Animal toxicity stud-
ies must first be done and under processes that are
called good laboratory practices (GLP). These studies
often require that more than one species be tested,
usually a rodent and another non-rodent species, to
ensure that anticipated and even unexpected toxicities
are identified and characterized so the material can be
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given safely in the doses that are anticipated in human
studies.
Animal studies are normally followed by three
phases of human drug development. Phase I studies
involve assessment of safety, tolerability, and phar-
macokinetics aimed at determining maximum toler-
ated doses and certain pharmacokinetic parameters.
Phase II studies are exploratory, dose ranging studies
in carefully selected patients with the target indica-
tion of interest to further define safety and tolerability
as well as demonstrate preliminary evidence of effi-
cacy. Finally, Phase III studies are then initiated to
confirm efficacy and safety in the patient popula-
tion most likely to receive treatment post-approval.
These large-scale studies are usually done in dupli-
cate, and require an extensive number of subjects to
provide adequate power to show that a clinical effect,
if present, can be observed. The complex develop-
ment and approval process for drugs therefore often
requires up to 10 years, and hundreds of millions of
dollars. In contrast, the approval process for medical
devices often is shorter and requires fewer numbers
of studies and subjects. Primarily, the device must be
shown to function appropriately for its intended use
without overt difficulties. However, because of recent
problems with medical devices, this process has been
made more rigorous. In some cases, it may now require
a similar series of studies to the approval process for
therapeutics.
As a result, although a research scientist often
thinks that a drug is ‘finished’ when research
ends and clinical development begins, it is just
the start of a long and arduous process to obtain
regulatory approval. It is clearly very important
to understand exactly how nanomaterials can be
developed into approved medicines and devices. As
part of that process, we at WIREs Nanomedicine
and Nanobiotechnology feel that the publication of
preclinical and clinical studies related to therapeutic
approval process is an important part of our
job. Therefore, we particularly encourage authors
to submit studies on therapeutic development of
nanomedicines to our publication. We feel that there
could be multiple aspects of these studies that would
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make excellent articles for WIREs Nanomedicine and
Nanobiotechnology.
One area of interest would be an overview on the
approach to obtaining regulatory approval for a new
therapeutic. Studies that outline how specific thera-
peutics are to be tested and evaluated, both in terms of
toxicity and clinical efficacy, would be important. Pub-
lishing this work would enhance our understanding
of the process of nanotherapeutic and device approval
as well as to get feedback from readers as to potential
improvements in this process. Improving the efficiency
of clinical trials is one important way to decrease the
cost and time involved in therapeutic development. If
we can help facilitate this goal through the publication
of preliminary proposals, we believe that it would be
an important goal for nanomedicine.
The second and most exciting area would be
the publication of the results of clinical trials with
nanomedicines. We encourage submission of the
results of clinical trials that have both positive and neg-
ative findings. The positive trials will tell us about new
therapeutics that are in development and present their
unique activities for us to understand. Negative clini-
cal trials may provide important lessons into problems
associated with the development of nanomedicines
or the use of nanomaterials in clinical trials. These
‘lessons learned’ may markedly improve the ability of
other individuals to develop therapeutics. Also, pub-
lishing summaries of regulatory interactions related to
development of nanomedicines would provide valu-
able insight into how nanotechnology is perceived
within the regulated environment. It would be impor-
tant to understand why a drug or a device has taken a
specific path toward the clinic and what type of results
will be or were necessary to achieve the approval. A
final type of article we feel would be interesting to
publish would be the personal perspectives of those
involved in obtaining drug approval. Understanding
the frustrations and challenges that are inherent in
this process should certainly help others who are
attempting to move products through development.
I hope you share my enthusiasm for the clinical
development of nanomedicines. Those involved in this
process have my utmost respect and I hope that they
will share their work with us. If nothing else, having an
open discussion about the hurdles in characterization
of nanomedicines, assessment of their safety in animals
and entry into clinical development will enhance the
number of products that will become nanomedicines
from nanomaterials.
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